Molecular dynamics study on the inhibition mechanisms of ReACp53 peptide for p53-R175H mutant aggregation

Jiangtao Lei1, Mengqiang Cai1, Yun Shen2

  • 1Institute of Space Science and Technology, Nanchang University, Xuefu Avenue 999, Nanchang City 330031, China. jiangtaolei@ncu.edu.cn.

Insights

The ReACp53 peptide inhibits p53 mutant aggregation by stabilizing its structure and blocking aggregation-prone regions. This molecular insight aids developing new cancer therapeutics targeting p53 aggregation.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Computational Biology

Background:

  • p53 mutant aggregation causes loss-of-function, dominant-negative, and gain-of-function effects, contributing to tumor growth.
  • Inhibiting p53 mutant aggregation is crucial for developing targeted cancer therapies.
  • The ReACp53 peptide shows therapeutic potential by inhibiting p53 mutant aggregation and restoring nuclear function.

Purpose of the Study:

  • To elucidate the molecular mechanism by which the ReACp53 peptide inhibits the aggregation of the p53 R175H mutant.
  • To investigate the structural and dynamic effects of ReACp53 on the p53 core domain using molecular dynamics simulations.

Main Methods:

  • All-atom molecular dynamics (MD) simulations were employed.
  • The study focused on the p53 core domain (p53C) of the R175H mutant.
  • Analysis involved assessing structural stability, flexibility, and peptide-protein interactions.

Main Results:

  • ReACp53 peptide stabilizes the secondary structure and reduces loop flexibility in the R175H mutant by enhancing intra-molecular interactions.
  • ReACp53 specifically binds to residues 180-233 of R175H mutant via hydrophobic and electrostatic interactions.
  • This binding protects the aggregation-prone segment (residues 182-213) from solvent exposure.

Conclusions:

  • ReACp53 inhibits R175H mutant aggregation by promoting a wild-type-like conformation and shielding aggregation-prone regions.
  • The findings provide crucial molecular insights into the anti-aggregation mechanism of ReACp53.
  • This understanding supports the development of novel therapeutics for aggregation-associated cancers.